Cite
HARVARD Citation
Yamauchi, M. et al. (2020). Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma. Clinical and translational gastroenterology. 11 (5), pp. e00179-. [Online].